Zobrazeno 1 - 1
of 1
pro vyhledávání: ''
Publikováno v:
Breathe, Vol 14, Iss 2, Pp e68-e71 (2018)
Pedersen, S S, Jensen-Fangel, S & Jeppesen, M 2018, ' Bridging for lung transplantation with lumacaftor/ivacaftor ', Breathe, bind 14, nr. 2, s. e68-e71 . https://doi.org/10.1183/20734735.019318
Pedersen, S S, Jensen-Fangel, S, Jeppesen, M & Søgaard, O S 2018, ' Bridging for lung transplantation with lumacaftor/ivacaftor ', Breathe, vol. 14, no. 2, pp. e68-e71 . https://doi.org/10.1183/20734735.019318
Breathe
Pedersen, S S, Jensen-Fangel, S & Jeppesen, M 2018, ' Bridging for lung transplantation with lumacaftor/ivacaftor ', Breathe, bind 14, nr. 2, s. e68-e71 . https://doi.org/10.1183/20734735.019318
Pedersen, S S, Jensen-Fangel, S, Jeppesen, M & Søgaard, O S 2018, ' Bridging for lung transplantation with lumacaftor/ivacaftor ', Breathe, vol. 14, no. 2, pp. e68-e71 . https://doi.org/10.1183/20734735.019318
Breathe
Cystic fibrosis (CF) is a multi-organ disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene, with consequent dysfunction of the CFTR channel. The most common mutation in CF is delta F508. CFTR-modulating therapy with